In any event, our results here suggest that the identification of non-toxic small molecules that specifically activate CHOP expression without activating other components of the ISR pathway might be extremely useful for developing lytic induction therapy for human EBV-positive gastric and NPC tumors. Here, DDIT3 is linked to nasopharyngeal carcinoma.